6-MeO-RU-28306
Pharmaceutical compound
From Wikipedia, the free encyclopedia
6-MeO-RU-28306, or 6-methoxy-RU-28306, also known as 4,α-methylene-5-methoxy-N,N-dimethyltryptamine (4,α-methylene-5-MeO-DMT), is a serotonin receptor modulator and a cyclized tryptamine and partial ergoline.[1] It is the 6-methoxy derivative of RU-28306 (4,α-methylene-DMT) and a cyclized derivative of 5-MeO-DMT.[1] The drug showed affinity for the serotonin-labeled serotonin 5-HT1 receptors and spiperone-labeled serotonin 5-HT2 receptors in rat frontal cortex membranes in vitro (IC50 = 96 nM and 1,756 nM, respectively).[1] 6-MeO-RU-28306 robustly reduced hypothalamic 5-hydroxyindoleacetic acid (5-HIAA) levels and increased circulating corticosterone levels in rodents in vivo, which are both measures of serotonin receptor agonist activity.[1] The chemical synthesis of 6-MeO-RU-28306 has been described.[1] 6-MeO-RU-28306 was first described in the scientific literature by 1988.[1]
- None
| Clinical data | |
|---|---|
| Other names | 6-Methoxy-RU-28306; 6-MeO-RU28306; 6-Methoxy-RU28306; 4,α-Methylene-5-methoxy-N,N-dimethyltryptamine; 4,α-Methylene-5-MeO-DMT |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H18N2O |
| Molar mass | 230.311 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- Partial lysergamide
- Bay R 1531 (LY-197206)